<!DOCTYPE html>
<html lang="pt-BR">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Asma (GINA 2025)</title>
    <link rel="stylesheet" href="style.css">
    <style>
        /* TEMA ROXO (ASMA/RESPIRAT√ìRIO CR√îNICO) */
        :root { --theme-asthma: #673AB7; } 
        
        .resumo-box {
            background: white;
            border-radius: 12px;
            padding: 20px;
            margin-bottom: 20px;
            box-shadow: 0 2px 6px rgba(0,0,0,0.04);
            border-left: 5px solid var(--theme-asthma);
        }

        .res-header { 
            font-size: 1.1rem; 
            font-weight: 800; 
            margin-bottom: 15px; 
            display: flex; 
            align-items: center; 
            gap: 10px; 
            color: #4527A0; 
            text-transform: uppercase;
            letter-spacing: 0.5px;
            border-bottom: 1px solid #D1C4E9;
            padding-bottom: 10px;
        }

        .res-content { font-size: 0.95rem; color: #444; line-height: 1.6; }
        
        /* Tabelas */
        .table-custom { width: 100%; border-collapse: collapse; margin: 10px 0; font-size: 0.85rem; }
        .table-custom th { background-color: #EDE7F6; color: #4527A0; padding: 8px; text-align: left; border: 1px solid #D1C4E9; }
        .table-custom td { padding: 8px; border: 1px solid #eee; }
        .table-custom tr:nth-child(even) { background-color: #FAFAFA; }

        /* Drugs */
        .drug-table { width: 100%; font-size: 0.85rem; margin-bottom: 20px; border-collapse: collapse; }
        .drug-table th { background: #ECEFF1; color: #37474F; text-align: left; padding: 8px; border-bottom: 2px solid #CFD8DC; }
        .drug-table td { border-bottom: 1px solid #eee; padding: 8px; vertical-align: middle; }
        .drug-name { font-weight: 700; color: #673AB7; display: block; font-size: 0.9rem; }
        
        /* TAG SUS */
        .tag-sus { 
            background-color: #2E7D32; color: white; 
            padding: 3px 8px; border-radius: 4px; 
            font-size: 0.75rem; font-weight: bold; 
            display: inline-block; margin-left: 5px;
            vertical-align: text-bottom;
        }

        /* Tracks GINA */
        .track-box { padding: 15px; border-radius: 8px; margin-bottom: 15px; border: 1px solid transparent; }
        .track-1 { background-color: #E8F5E9; border-color: #C8E6C9; border-left: 5px solid #2E7D32; }
        .track-2 { background-color: #FFF3E0; border-color: #FFE0B2; border-left: 5px solid #EF6C00; }
        .track-title { font-weight: 800; display: block; margin-bottom: 5px; text-transform: uppercase; font-size: 0.9rem; }

        /* Section Dividers */
        .section-title { 
            background: var(--theme-asthma); color: white; 
            padding: 10px 15px; border-radius: 8px; 
            font-weight: bold; margin: 30px 0 15px 0; 
            text-align: center; text-transform: uppercase;
            box-shadow: 0 4px 6px rgba(103, 58, 183, 0.2);
        }

        /* Check lists */
        .check-list li { margin-bottom: 6px; }
        .check-list li::before { content: "‚Ä¢ "; color: var(--theme-asthma); font-weight: bold; }

        /* Child Criteria Box */
        .child-box { background: #E3F2FD; border: 1px dashed #90CAF9; padding: 10px; border-radius: 6px; margin-top: 15px; }

        /* Biomarker Box */
        .bio-box { background: #F3E5F5; border-left: 4px solid #AB47BC; padding: 12px; margin-top: 15px; border-radius: 4px; }

        .ref-section { margin-top: 40px; font-size: 0.75rem; color: #777; border-top: 1px solid #ddd; padding-top: 20px; }
    </style>
</head>
<body>

    <header class="app-header">
        <button class="back-btn" onclick="window.location.href='resumos.html'">‚¨Ö</button>
        <div class="app-title">Asma (GINA 2025)</div>
    </header>

    <div class="container">

        <div class="section-title">ü´Å Quadro Cl√≠nico T√≠pico</div>

        <div class="resumo-box">
            <div class="res-header">üå¨Ô∏è Sintomas e Padr√µes</div>
            <div class="res-content">
                <p>Doen√ßa heterog√™nea caracterizada por inflama√ß√£o cr√¥nica das vias a√©reas.</p>
                <ul class="check-list">
                    <li><strong>Sintomas Cardinais:</strong> Sibil√¢ncia (chiado), falta de ar (dispneia), opress√£o tor√°cica e tosse.</li>
                    <li><strong>Variabilidade (Marca registrada):</strong> Sintomas variam ao longo do tempo e em intensidade.</li>
                    <li><strong>Piora Noturna/Matinal:</strong> Comum despertar com sintomas ou piora logo cedo.</li>
                    <li><strong>Gatilhos:</strong> Exerc√≠cio, risada, al√©rgenos, ar frio, infec√ß√µes virais.</li>
                </ul>
                <p style="font-size:0.85rem; margin-top:10px; background:#F3E5F5; padding:8px; border-radius:6px;">
                    <strong>üö© Aten√ß√£o:</strong> Tosse isolada sem outros sintomas respirat√≥rios raramente √© asma.
                </p>
            </div>
        </div>

        <div class="section-title">üìê Diagn√≥stico e Crit√©rios</div>

        <div class="resumo-box">
            <div class="res-header">‚öôÔ∏è Limita√ß√£o ao Fluxo A√©reo (Espirometria)</div>
            <div class="res-content">
                <p>A confirma√ß√£o do diagn√≥stico requer a demonstra√ß√£o de <strong>Limita√ß√£o Vari√°vel ao Fluxo A√©reo Expirat√≥rio</strong>.</p>
                
                <h4 style="color:#4527A0;">1. Crit√©rios de Obstru√ß√£o</h4>
                <table class="table-custom">
                    <tr><th>Par√¢metro</th><th>Adultos</th><th>Crian√ßas</th></tr>
                    <tr><td><strong>√çndice de Tiffeneau (VEF1/CVF)</strong></td><td>Reduzido (Geralmente < 0,75 ‚Äì 0,80)</td><td>Reduzido (Geralmente < 0,90)</td></tr>
                </table>

                <h4 style="color:#4527A0; margin-top:15px;">2. Crit√©rios de Reversibilidade (Variabilidade)</h4>
                <table class="table-custom">
                    <tr><th>Teste</th><th>Crit√©rio Positivo</th></tr>
                    <tr><td><strong>Prova Broncodilatadora (PBD)</strong><br><small>(Ap√≥s 200-400mcg salbutamol)</small></td><td><strong>Adultos:</strong> Aumento do VEF1 > 12% <strong>E</strong> > 200 ml.<br><strong>Crian√ßas:</strong> Aumento do VEF1 > 12% do previsto.</td></tr>
                    <tr><td><strong>Variabilidade Diurna do PFE</strong><br><small>(M√©dia de 2 semanas)</small></td><td><strong>Adultos:</strong> > 10%<br><strong>Crian√ßas:</strong> > 13%</td></tr>
                    <tr><td><strong>Teste Terap√™utico</strong><br><small>(4 semanas de tratamento)</small></td><td>Melhora significativa do VEF1 ou PFE ap√≥s uso de corticoide inalat√≥rio.</td></tr>
                </table>

                <div class="bio-box">
                    <strong>üß¨ Biomarcadores e Inflama√ß√£o Tipo 2 (T2)</strong>
                    <p style="font-size:0.85rem; margin-top:5px;">
                        A GINA incentiva a avalia√ß√£o do fen√≥tipo inflamat√≥rio. Marcadores elevados sugerem boa resposta a corticoides (CI) e biol√≥gicos espec√≠ficos.
                    </p>
                    <ul class="check-list" style="font-size:0.85rem;">
                        <li><strong>Eosin√≥filos no Sangue:</strong> > 150 c√©lulas/¬µL (Elevado) / > 300 (Muito elevado).</li>
                        <li><strong>FeNO (√ìxido N√≠trico Exalado):</strong> Marcador de inflama√ß√£o eosinof√≠lica nas vias a√©reas.
                            <br><em>> 20 ppb:</em> Suporta diagn√≥stico de asma T2 e prev√™ resposta a CI.
                            <br><em>Nota:</em> FeNO isolado n√£o confirma nem exclui asma.
                        </li>
                    </ul>
                </div>

                <div class="child-box">
                    <h4 style="color:#0277BD; margin-bottom:5px;">üë∂ Crian√ßas Pequenas (< 5 anos)</h4>
                    <p>Diagn√≥stico √© <strong>cl√≠nico e probabil√≠stico</strong> (espirometria invi√°vel).</p>
                    <ul class="check-list">
                        <li><strong>Sintomas:</strong> Tosse/chiado recorrentes (> 10 dias durante infec√ß√µes virais).</li>
                        <li><strong>Atividade:</strong> Sintomas ao rir, chorar ou brincar.</li>
                        <li><strong>Hist√≥ria:</strong> Eczema at√≥pico, rinite ou asma em parentes de 1¬∫ grau.</li>
                        <li><strong>Prova Terap√™utica (Ouro):</strong> Melhora cl√≠nica evidente ap√≥s 2-3 meses de CI e piora ap√≥s suspens√£o.</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="section-title">üíä Manejo (GINA 2025)</div>

        <div class="resumo-box">
            <div class="res-header">üö¶ Vias de Tratamento (Tracks)</div>
            <div class="res-content">
                <p>Para Adultos e Adolescentes, o GINA divide o tratamento em dois caminhos ("Tracks").</p>
                
                <div class="track-box track-1">
                    <span class="track-title" style="color:#1B5E20;">VIA 1 (PREFERENCIAL) ‚≠ê</span>
                    <p style="margin:0;"><strong>Al√≠vio (Resgate):</strong> CI-Formoterol em baixa dose.<br>
                    <strong>Manuten√ß√£o:</strong> CI-Formoterol (MART) ou uso apenas se necess√°rio (Steps 1-2).<br>
                    <em>Vantagem:</em> Reduz risco de exacerba√ß√£o grave comparado ao SABA isolado.</p>
                </div>

                <div class="track-box track-2">
                    <span class="track-title" style="color:#E65100;">VIA 2 (ALTERNATIVA)</span>
                    <p style="margin:0;"><strong>Al√≠vio:</strong> SABA (Salbutamol).<br>
                    <strong>Manuten√ß√£o:</strong> CI di√°rio (Obrigat√≥rio ades√£o rigorosa).<br>
                    <em>Risco:</em> Se o paciente esquecer o CI e usar s√≥ SABA, o risco de crise aumenta.</p>
                </div>
            </div>
        </div>

        <div class="resumo-box">
            <div class="res-header">‚öñÔ∏è Posologia: Corticoides Inalat√≥rios (GINA 2025)</div>
            <div class="res-content">
                <p>Defini√ß√£o de dose Baixa, M√©dia e Alta (mcg/dia). <strong>Aten√ß√£o:</strong> Doses dependem do dispositivo.</p>
                
                <h4 style="color:#4527A0; margin-top:15px; background:#EDE7F6; padding:5px;">Adultos e Adolescentes (>12 anos)</h4>
                <table class="table-custom" style="font-size:0.8rem;">
                    <tr>
                        <th>F√°rmaco</th>
                        <th>Dose Baixa (mcg)</th>
                        <th>Dose M√©dia (mcg)</th>
                        <th>Dose Alta (mcg)</th>
                    </tr>
                    <tr>
                        <td><strong>Beclometasona</strong> (HFA - Spray)</td>
                        <td>200 ‚Äì 500</td>
                        <td>> 500 ‚Äì 1000</td>
                        <td>> 1000</td>
                    </tr>
                    <tr>
                        <td><strong>Budesonida</strong> (DPI - P√≥)</td>
                        <td>200 ‚Äì 400</td>
                        <td>> 400 ‚Äì 800</td>
                        <td>> 800</td>
                    </tr>
                    <tr>
                        <td><strong>Fluticasona Prop.</strong> (DPI - P√≥)</td>
                        <td>100 ‚Äì 250</td>
                        <td>> 250 ‚Äì 500</td>
                        <td>> 500</td>
                    </tr>
                    <tr>
                        <td><strong>Mometasona</strong> (DPI - P√≥)</td>
                        <td>200</td>
                        <td>400</td>
                        <td>> 400</td>
                    </tr>
                </table>

                <h4 style="color:#4527A0; margin-top:20px; background:#E3F2FD; padding:5px;">Crian√ßas (6-11 anos)</h4>
                <table class="table-custom" style="font-size:0.8rem;">
                    <tr>
                        <th>F√°rmaco</th>
                        <th>Dose Baixa (mcg)</th>
                        <th>Dose M√©dia (mcg)</th>
                        <th>Dose Alta (mcg)</th>
                    </tr>
                    <tr>
                        <td><strong>Beclometasona</strong> (HFA - Spray)</td>
                        <td>100 ‚Äì 200</td>
                        <td>> 200 ‚Äì 400</td>
                        <td>> 400</td>
                    </tr>
                    <tr>
                        <td><strong>Budesonida</strong> (DPI/Spray)</td>
                        <td>100 ‚Äì 200</td>
                        <td>> 200 ‚Äì 400</td>
                        <td>> 400</td>
                    </tr>
                    <tr>
                        <td><strong>Fluticasona Prop.</strong> (Spray)</td>
                        <td>50 ‚Äì 100</td>
                        <td>> 100 ‚Äì 200</td>
                        <td>> 200</td>
                    </tr>
                </table>

                <h4 style="color:#4527A0; margin-top:20px; background:#FFF3E0; padding:5px;">Crian√ßas Pequenas (< 5 anos)</h4>
                <p style="font-size:0.85rem;">Sugest√£o de <strong>Dose Baixa Di√°ria</strong> para in√≠cio de tratamento:</p>
                <ul class="check-list">
                    <li><strong>Budesonida (Nebuliza√ß√£o):</strong> 500 mcg/dia.</li>
                    <li><strong>Fluticasona (Spray + Espa√ßador):</strong> 50 mcg/dia.</li>
                    <li><strong>Beclometasona (Spray + Espa√ßador):</strong> 100 mcg/dia.</li>
                </ul>
            </div>
        </div>

        <div class="section-title">üíä Medicamentos Dispon√≠veis (Brasil/SUS)</div>

        <div class="resumo-box">
            <div class="res-header">üìã Lista Pr√°tica</div>
            <div class="res-content">
                <table class="drug-table">
                    <tr><th>Classe</th><th>F√°rmaco</th><th>Disponibilidade</th></tr>
                    <tr>
                        <td><strong>SABA (Al√≠vio)</strong></td>
                        <td><span class="drug-name">Salbutamol (Aerolin)</span></td>
                        <td><span class="tag-sus">SUS</span> (UBS)</td>
                    </tr>
                    <tr>
                        <td><strong>CI (Manuten√ß√£o)</strong></td>
                        <td><span class="drug-name">Beclometasona (HFA)</span></td>
                        <td><span class="tag-sus">SUS</span> (UBS - Dose habitual: 200-250mcg/puff)</td>
                    </tr>
                    <tr>
                        <td><strong>CI (Manuten√ß√£o)</strong></td>
                        <td><span class="drug-name">Budesonida</span></td>
                        <td><span class="tag-sus">SUS</span> (Farm√°cia Popular)</td>
                    </tr>
                    <tr>
                        <td><strong>CI + LABA</strong></td>
                        <td><span class="drug-name">Budesonida + Formoterol (Alenia)</span></td>
                        <td><span class="tag-sus">SUS</span> (Alto Custo - Exige LME/Espirometria)</td>
                    </tr>
                    <tr>
                        <td><strong>CI + LABA</strong></td>
                        <td><span class="drug-name">Fluticasona + Salmeterol (Seretide)</span></td>
                        <td>Privado</td>
                    </tr>
                </table>
            </div>
        </div>

        <div class="ref-section">
            <strong>Refer√™ncia:</strong><br>
            Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2025. Updated November 2025.<br>
            SBPT. Recomenda√ß√µes para o manejo da asma da Sociedade Brasileira de Pneumologia e Tisiologia - 2021.
        </div>

    </div>

</body>
</html>